A detailed history of Royal Bank Of Canada transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,162 shares of OVID stock, worth $5,368. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,162
Previous 5,539 6.81%
Holding current value
$5,368
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.75 - $1.3 $282 - $490
-377 Reduced 6.81%
5,162 $6,000
Q2 2024

Aug 14, 2024

BUY
$0.7 - $3.34 $2,298 - $10,965
3,283 Added 145.52%
5,539 $4,000
Q1 2024

Nov 05, 2024

SELL
$2.72 - $4.04 $8,929 - $13,263
-3,283 Reduced 59.27%
2,256 $6,000
Q1 2024

May 15, 2024

SELL
$2.72 - $4.04 $57,454 - $85,336
-21,123 Reduced 90.35%
2,256 $6,000
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $31,468 - $39,916
10,560 Added 82.38%
23,379 $75,000
Q3 2023

Nov 14, 2023

BUY
$3.23 - $3.97 $21,311 - $26,194
6,598 Added 106.06%
12,819 $49,000
Q2 2023

Aug 14, 2023

BUY
$2.53 - $3.89 $15,594 - $23,977
6,164 Added 10814.04%
6,221 $20,000
Q1 2023

May 15, 2023

BUY
$1.88 - $2.85 $1 - $2
1 Added 1.79%
57 $0
Q4 2022

Feb 14, 2023

SELL
$1.43 - $1.89 $576 - $761
-403 Reduced 87.8%
56 $0
Q3 2022

Nov 14, 2022

BUY
$1.84 - $2.26 $844 - $1,037
459 New
459 $1,000
Q2 2022

Aug 15, 2022

SELL
$1.69 - $3.31 $1,622 - $3,177
-960 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.65 - $3.49 $1,431 - $1,884
-540 Reduced 36.0%
960 $3,000
Q4 2021

Feb 14, 2022

SELL
$3.13 - $3.73 $18,780 - $22,380
-6,000 Reduced 80.0%
1,500 $5,000
Q3 2021

Nov 15, 2021

SELL
$3.31 - $4.04 $57,001 - $69,572
-17,221 Reduced 69.66%
7,500 $25,000
Q2 2021

Aug 16, 2021

BUY
$3.3 - $4.49 $81,579 - $110,997
24,721 New
24,721 $97,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $73.2M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.